Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:31:23 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:SEOVF - SERNOVA BIOTHERAPEUTICS INC - https://www.sernova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SEOVF - Qnot subscribed0.11-0.00088-0.8110.811140.11  0.1104  0.10540.165  0.086715:51:34Dec 1615 min RT 2¢

Recent Trades - Last 10 of 14
Time ETExPriceChangeVolume
15:51:34Q0.11-0.000886,000
15:10:03Q0.11-0.0008812,500
15:07:59Q0.11-0.0008813,500
15:07:59Q0.11-0.000888,500
15:07:59Q0.11-0.000888,000
13:32:53Q0.1086-0.002281,000
13:17:59Q0.1054-0.0054810,600
13:17:59Q0.1055-0.0053843,500
13:17:59Q0.1055-0.005383,000
13:17:59Q0.1055-0.00538500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-16 12:00U:SEOVFNews ReleaseFrom Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
2025-10-01 07:01U:SEOVFNews ReleaseSernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
2025-09-23 08:01U:SEOVFNews ReleaseSernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
2025-09-08 09:47U:SEOVFNews ReleaseSernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference
2025-07-09 08:30U:SEOVFNews ReleaseSernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
2025-06-02 16:15U:SEOVFNews ReleaseSernova Appoints Jonathan Rigby as Interim Chair
2025-05-26 00:00U:SEOVFNews ReleaseChair of Sernova Biotherapeutics Resigns
2025-05-22 07:00U:SEOVFNews ReleaseSernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
2025-05-14 07:00U:SEOVFNews ReleaseSernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
2025-04-17 08:00U:SEOVFNews ReleaseSernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans
2025-04-15 16:06U:SEOVFNews ReleaseSernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med
2025-04-01 08:00U:SEOVFNews ReleaseSernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch(TM) Bio-Hybrid Organ for Treatment of Type 1 Diabetes
2025-03-10 08:00U:SEOVFNews ReleaseSernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
2025-03-05 08:00U:SEOVFNews ReleaseSernova Biotherapeutics Secures $1 Million Convertible Debt Financing
2025-03-03 09:00U:SEOVFNews ReleaseSernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism